July 25, 2024 07:29 AM EDTUpdated 10:23 AM
Pharma
Manufacturing

Sanofi eyes RSV an­ti­body for its next block­buster while Dupix­ent brings in record sales

Anna Brown

News Reporter

Sanofi’s RSV an­ti­body Bey­for­tus is still on track to reach block­buster sta­tus this year as the com­pa­ny ex­pands man­u­fac­tur­ing ca­pac­i­ty, ac­cord­ing to re­marks made Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times